Cadrenal Therapeutics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.7M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.05%
- Volume
- 59.9K
About
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Quick stats
Shares outstanding3.6M
Computed float2.2M
Float / shares61.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001937993
Websitehttps://www.cadrenal.com
AI Summary
AI-generated1/16
majorbullishearnings
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Cadrenal reported a Q2 net loss of $3.3 million, narrowing from $3.7 million in the prior year, with cash and equivalents of $4.2 million as of early August following a $3.0 million private placement.
Operationally, the company announced positive Phase 2 data for CAD-1005, demonstrating an absolute reduction of more than 25% in thrombotic events, and confirmed regulatory guidance for a Phase 3 pathway.
Management has launched a structured partnering process to pursue strategic out-licensing and commercialization for its Cardiac Acute Critical Care Franchise, while also submitting a request for Rare Pediatric Disease Designation for tecarfarin.
Red flags
- Cash runway limited to Q1 2027
- Existing cash resources insufficient to complete clinical trials without additional funding